Recurrent Ovarian Cancer

Oncology
3
Pipeline Programs
3
Companies
9
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

ADC
1100%
+ 2 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
Mirvetuximab SoravtansinePhase 2ADC5 trials
Active Trials
NCT06890338Recruiting140Est. Feb 2030
NCT07059845Recruiting320Est. Jan 2029
NCT06365853Recruiting100Est. Jun 2027
+2 more trials
Corcept Therapeutics
Corcept TherapeuticsCA - Redwood City
1 program
1
RelacorilantPhase 21 trial
Active Trials
NCT03776812Completed178Est. Jul 2023
Novartis
NovartisBASEL, Switzerland
1 program
1
CPI-0209Phase 11 trial
Active Trials
NCT05942300Recruiting30Est. Dec 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
AbbVieMirvetuximab Soravtansine
Corcept TherapeuticsRelacorilant
NovartisCPI-0209

Clinical Trials (9)

Total enrollment: 1,478 patients across 9 trials

NCT04209855AbbVieMirvetuximab Soravtansine

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

Start: Dec 2019Est. completion: Oct 2024453 patients
Phase 3Completed
NCT06890338AbbVieMirvetuximab Soravtansine

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Start: Nov 2025Est. completion: Feb 2030140 patients
Phase 2Recruiting
NCT07059845AbbVieMirvetuximab Soravtansine

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Start: Nov 2025Est. completion: Jan 2029320 patients
Phase 2Recruiting
NCT06365853AbbVieMirvetuximab Soravtansine

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

Start: Jul 2024Est. completion: Jun 2027100 patients
Phase 2Recruiting
NCT05887609AbbVieMirvetuximab Soravtansine

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Start: Oct 2023Est. completion: Oct 202853 patients
Phase 2Recruiting
NCT05456685AbbVieMirvetuximab Soravtansine

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Start: Sep 2022Est. completion: Nov 2026125 patients
Phase 2Active Not Recruiting
NCT05041257AbbVieMirvetuximab Soravtansine

Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers

Start: Oct 2021Est. completion: Dec 202479 patients
Phase 2Completed
NCT03776812Corcept TherapeuticsRelacorilant

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Start: Apr 2019Est. completion: Jul 2023178 patients
Phase 2Completed
NCT05942300NovartisCPI-0209

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Start: Jan 2024Est. completion: Dec 202830 patients
Phase 1Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 actively recruiting trials targeting 1,478 patients
3 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)